Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor

被引：133

作者：

McCauley, John A. ^{[1
]}

McIntyre, Charles J. ^{[1
]}

Rudd, Michael T. ^{[1
]}

Nguyen, Kevin T. ^{[1
]}

Romano, Joseph J. ^{[1
]}

Butcher, John W. ^{[1
]}

Gilbert, Kevin F. ^{[1
]}

Bush, Kimberly J. ^{[1
]}

Holloway, M. Katharine ^{[2
]}

Swestock, John ^{[1
]}

Wan, Bang-Lin ^{[1
]}

Carroll, Steven S. ^{[3
]}

DiMuzio, Jillian M. ^{[3
]}

Graham, Donald J. ^{[3
]}

Ludmerer, Steven W. ^{[3
]}

Mao, Shi-Shan ^{[3
]}

Stahlhut, Mark W. ^{[3
]}

Fandozzi, Christine M. ^{[4
]}

Trainor, Nicole ^{[4
]}

Olsen, David B. ^{[3
]}

Vacca, Joseph P. ^{[1
]}

Liverton, Nigel J. ^{[1
]}

机构：

[1] Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA

[2] Merck Res Labs, Dept Mol Syst, West Point, PA 19486 USA

[3] Merck Res Labs, Dept Antiviral Res, West Point, PA 19486 USA

[4] Merck Res Labs, Dept Drug Metab, West Point, PA 19486 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2010年 / 53卷 / 06期

关键词：

OLEFIN-METATHESIS CATALYSTS; RING-CLOSING METATHESIS; PRECLINICAL PROFILE; INITIAL TREATMENT; IN-VITRO; POTENT; SCH-503034; RIBAVIRIN; EFFICIENT; INTERFERON-ALPHA-2B;

D O I：

10.1021/jm9015526

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A new class of H CV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a molecular-modeling derived strategy. Exploration of the P2 heterocyclic region, the P2 to P4 linker, and the PI side chain of this class of compounds via a modular synthetic strategy allowed for the optimization of enzyme potency, cellular activity, and rat liver exposure following oral closing. These studies led to the identification of clinical candidate 35b (vaniprevir, MK-7009), which is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes and has good plasma exposure and excellent liver exposure in multiple species.

引用

页码：2443 / 2463

页数：21

共 54 条

[31]

McPhee F., 2004, WO, Patent No. 2004094452

[32] Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro [J].

Migliaccio, G ;

Tomassini, JE ;

Carroll, SS ;

Tomei, L ;

Altamura, S ;

Bhat, B ;

Bartholomew, L ;

Bosserman, MR ;

Ceccacci, A ;

Colwell, LF ;

Cortese, R ;

De Francesco, R ;

Eldrup, AB ;

Getty, KL ;

Hou, XS ;

LaFemina, RL ;

Ludmerer, SW ;

MacCoss, M ;

McMasters, DR ;

Stahlhut, MW ;

Olsen, DB ;

Hazuda, DJ ;

Flores, OA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (49) :49164-49170

[33] Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease [J].

Perni, RB ;

Almquist, SJ ;

Byrn, RA ;

Chandorkar, G ;

Chaturvedi, PR ;

Courtney, LF ;

Decker, CJ ;

Dinehart, K ;

Gates, CA ;

Harbeson, SL ;

Heiser, A ;

Kalkeri, G ;

Kolaczkowski, E ;

Lin, K ;

Luong, YP ;

Rao, BG ;

Taylor, WP ;

Thomson, JA ;

Tung, RD ;

Wei, YY ;

Kwong, AD ;

Lin, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) :899-909

[34] INHIBITION OF GAMMA-BUTYROBETAINE HYDROXYLASE BY CYCLOPROPYL-SUBSTITUTED GAMMA-BUTYROBETAINES [J].

PETTER, RC ;

BANERJEE, S ;

ENGLARD, S .

JOURNAL OF ORGANIC CHEMISTRY, 1990, 55 (10) :3088-3097

[35] Discovery of the HCVNS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II.: Key steps in structure-based optimization [J].

Prongay, Andrew J. ;

Guo, Zhuyan ;

Yao, Nanhua ;

Pichardo, John ;

Fischmann, Thierry ;

Strickland, Corey ;

Myers, Joseph, Jr. ;

Weber, Patricia C. ;

Beyer, Brian M. ;

Ingram, Richard ;

Hong, Zhi ;

Prosise, Winifred W. ;

Ramanathan, Lata ;

Taremi, S. Shane ;

Yarosh-Tomaine, Taisa ;

Zhang, Rumin ;

Senior, Mary ;

Yang, Rong-Sheng ;

Malcolm, Bruce ;

Arasappan, Ashok ;

Bennett, Frank ;

Bogen, Stephane L. ;

Chen, Kevin ;

Jao, Edwin ;

Liu, Yi-Tsung ;

Lovey, Raymond G. ;

Saksena, Anil K. ;

Venkatraman, Srikanth ;

Girijavallabhan, Viyyoor ;

Njoroge, F. George ;

Madison, Vincent .

JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (10) :2310-2318

[36]

Raboisson P. J.-M. B., 2007, [No title captured], Patent No. [2007014926A1, 2007014926, WO2007014926A1]

[37] Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350 [J].

Raboisson, Pierre ;

de Kock, Herman ;

Rosenquist, Asa ;

Nilsson, Magnus ;

Salvador-Oden, Lourdes ;

Lin, Tse-I ;

Roue, Natalie ;

Ivanov, Vladimir ;

Wahling, Horst ;

Wickstrom, Kristina ;

Hamelink, Elizabeth ;

Edlund, Michael ;

Vrang, Lotta ;

Vendeville, Sandrine ;

Van de Vreken, Wim ;

McGowan, David ;

Tahri, Abdellah ;

Hu, Lili ;

Boutton, Carlo ;

Lenz, Oliver ;

Delouvroy, Frederic ;

Pille, Geert ;

Surleraux, Dominique ;

Wigerinck, Piet ;

Samuelsson, Bertil ;

Simmen, Kenneth .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (17) :4853-4858

[38] Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior [J].

Rajagopalan, Ravi ;

Misialck, Shawn ;

Stevens, Sarah K. ;

Myszka, David G. ;

Brandhuber, Barbara J. ;

Ballard, Joshua A. ;

Andrews, Steven W. ;

Seiwert, Scott D. ;

Kossen, Karl .

BIOCHEMISTRY, 2009, 48 (11) :2559-2568

[39]

RIPKA A, 2004, Patent No. 2004048802

[40] Liver disease as a major cause of death among HIV infected patients:: role of hepatitis C and B viruses and alcohol [J].

Salmon-Ceron, D ;

Lewden, C ;

Morlat, P ;

Bévilacqua, S ;

Jougla, E ;

Bonnet, F ;

Héripret, L ;

Costagliola, D ;

May, T ;

Chêne, G .

JOURNAL OF HEPATOLOGY, 2005, 42 (06) :799-805

← 1 2 3 4 5 6 →